bexarotene

Type: Keyphrase
Name: bexarotene
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

New guidelines address primary cutaneous T-cell lymphoproliferative disorders

HOLLYWOOD, FLA. – The treatment of patients with lymphomatoid papulosis depends on the presentation, according to new National Comprehensive Cancer Network guidelines for managing primary cutaneous CD30+ T-cell lymphoproliferative disorders.No treatment ... [Published Oncology Report - Apr 15 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Tumor-initiating cells and methods of use

Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the ... [Published PharmCast - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

A masked diboron in Cu-catalysed borylation reaction: Highly regioselective formal hydroboration of alkynes for synthesis of branched alkenylborons

The use of a masked diboron as a boron source in the presence of a Cu-N-heterocyclic carbene (NHC) catalyst enables alkyl-, aryl-, heteroatom- and silyl-substituted terminal alkynes to undergo α-selective formal hydroboration to give diverse branched ... [Published RSC - Apr 08 2014]
First reported Feb 14 2014 - Updated Feb 14 2014 - 1 reports

TARGRETIN (Bexarotene) Capsule, Liquid Filled [Valeant Pharmaceuticals North America LLC]

First reported Dec 18 2013 - Updated Dec 18 2013 - 1 reports

Mylan announces settlement agreement for first-to-file generic version of TARGRETIN

Mylan has announced that its subsidiary Mylan Pharmaceuticals and partner, Banner Pharmacaps, have entered into a settlement and license agreement with Eisai and Valeant Pharmaceuticals Luxembourg that will resolve patent litigation related to Bexarotene ... [Published Pharmaceutical Business Review - Dec 18 2013]

Quotes

"Even though many patients actually have intermittent recurrent disease ... the death rate from LyP is zero. So this is a very manageable disease; don’t overtreat these tumors" he said

More Content

All (5) | News (4) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New guidelines address primary cutaneous T-cell... [Published Oncology Report - Apr 15 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
A masked diboron in Cu-catalysed borylation rea... [Published RSC - Apr 08 2014]
TARGRETIN (Bexarotene) Capsule, Liquid Filled [... [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2014]
Mylan announces settlement agreement for first-... [Published Pharmaceutical Business Review - Dec 18 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
TARGRETIN (Bexarotene) Capsule, Liquid Filled [... [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2014]
Updated Date: Feb 14, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.